IVIG modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease
US7968293B2 · kind B2 · utility
9Cited by
0References
13Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 11, 2008 |
| Grant date | Jun 28, 2011 |
| Priority date | — |
| Expiry date | Aug 28, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods for providing a prognosis of treatment of diseases associated with inflammatory disease of the brain, including MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease using molecular markers that are shown to be overexpressed or underexpressed in patients treated with intravenous immunoglobulins (IVIG). Also provided are methods to identify compounds that are useful for the treatment or prevention of MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.